freeze-dried powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Peptides are susceptible to hydrolysis, oxidation, and aggregation, and BPC-157 is no exception. The lyophilized powder form is generally more stable than a solution because residual moisture is low and molecular mobility is reduced. Once dissolved, the peptide is exposed to water, oxygen, and trace metal ions that accelerate degradation. Light exposure and repeated freeze-thaw cycles are also commonly cited as sources of loss. These general principles guide most handling recommendations found in supplier documentation.
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
==== Marc Tarabella ==== On 2 February 2023, the European Parliament removed Marc Tarabella's legal immunity; Tarabella was present and voted. Marc Tarabella was arrested on 10 February 2023 in Anthisnes where he is mayor. On 11 February, he was charged with corruption, money laundering, and participation in a criminal organisation, and incarcerated in Prison de Saint-Gilles. Tarabella's lawyer, Maxim Töller, has asked for the dismissal of the investigating judge, Michel Claise, on the grounds that "the judge clearly seems to take for granted the contested facts that are the subject of the investigation he is leading." On 20 February, the Federal Prosecutor's Office said that Claise opposed Töller's recusal motion, so the Federal Prosecutor's Office is obliged to refer Töller's motion to the Brussels Court of Appeal, who have eight days to decide whether or not the investigating judge should be removed from the case. In June 2023 the office of Tarabella was raided by police for the first time.
The earliest fossilised evidence of bone marrow was discovered in 2014 in Eusthenopteron, a lobe-finned fish which lived during the Devonian period approximately 370 million years ago. Scientists from Uppsala University and the European Synchrotron Radiation Facility used X-ray synchrotron microtomography to study the fossilised interior of the skeleton's humerus, finding organised tubular structures akin to modern vertebrate bone marrow. Eusthenopteron is closely related to the early tetrapods, which ultimately evolved into the land-dwelling mammals and reptiles of the present day.
Subcutaneous injection of racemic synephrine into rabbits was reported to cause a large rise in blood sugar. In experiments on anesthetized cats, Papp and Szekeres found that synephrine (stereochemistry unspecified) raised the thresholds for auricular and ventricular fibrillation, an indication of anti-arrhythmic properties. Evidence that synephrine might have some central effects comes from the research of Song and co-workers, who studied the effects of synephrine in mouse models of anti-depressant activity. These researchers observed that oral doses of 0.3 – 10 mg/kg of racemic synephrine were effective in shortening the duration of immobility produced in the assays, but did not cause any changes in spontaneous motor activity in separate tests. This characteristic immobility could be counteracted by the pre-administration of prazosin. Subsequent experiments using the individual enanatiomers of synephrine revealed that although the d-isomer significantly reduced the duration of immobility in the tail suspension test, at an oral dose of 3 mg/kg, the l-isomer had no effect at the same dose. In mice pre-treated with reserpine, an oral dose of 0.3 mg/kg d-synephrine significantly reversed the hypothermia, while l-synephrine required a dose of 1 mg/kg to be effective. Experiments with slices of cerebral cortex taken from rat brain showed that d-synephrine inhibited the uptake of [3H]-norepinephrine with an IC50 = 5.8 μM; l-synephrine was less potent (IC50 = 13.5 μM).
=== Refugee Lodges of Hispaniola === In 1748, on Cuba's neighboring island of Hispaniola, Freemasonry in Haiti was established by the Grande Loge de France with the St. Jean de Jérusalem Ecossais (English: St. John of Jerusalem) in Cap-Français, Saint-Domingue (known today as Haiti). The second Haitain Lodge was chartered in 1765 at Los Cayos, called Les Frères Réunis No. 1 (English: Reunited Brothers). When the Haitian Revolution started, a mass exodus of French and Saint-Domingue Creole refugee emigres left Saint-Domingue and settled in Cuba. Freemasonry was allowed to continue for some time during the war in Saint-Domingue, where Huet de la Chapelle had become the Grand Master of the French Provincial Grand Loge in 1795, until a change in government forced the Haitian Lodges to flee the island and relocate elsewhere. As that conflict then spilled over the border into Santo Domingo (known today as the Dominican Republic), the Eastern half of that island also experienced a wave of emigration as Spaniards fled the colony. Most of these refugees from Saint-Domingue and Santo Domingo landed in the port towns of Oriente Province, especially Baracoa and Santiago de Cuba. In 1798, La Bénéfique Concorde was reestablished in Baracoa, La Persévérance was reestablished in Santiago de Cuba, and La Concorde L'Amitié relocated to Havana. The charters for these French Lodges, however, specifically limited their activities to Hispaniola.
=== Antibody identification === Antibodies to blood group system antigens and their characteristics must be identified when such antibodies are detected in a potential recipient's serum or plasma. The specificity of the antibody aids the medical laboratory scientist in determining if the antibody is clinically significant. Antibody identification is a very laborious process. Characteristics of clinically significant antibodies include: reactive at body temperature (37°C), immunoglobulin (Ig) class G, IgM that reacts at body temperature, ability to cross the placenta, ability to cause red blood cell destruction, and/or antibodies directed against commonly known clinically significant red cell antigens. For example, if an individual is exposed to a red cell antigen (via blood transfusion, pregnancy, stem-cell transplant) that they do not inherently possess, they may form a clinically significant antibody directed against that antigen. If a patient receives a transfusion of packed red blood cells possessing the Kell antigen (big K or simply K), they may form an antibody called anti-K (anti big K). Subsequent transfusions with K-positive packed red blood cells would cause an immediate hemolytic transfusion reaction. The K antibody reacts at 37°C, is IgG, capable of crossing the placenta, and known to cause immediate red blood cell destruction. The presence of autoantibodies directed against self red blood cell antigens can complicate the antibody identification process.
Sources: en.wikipedia.org
== Clinical development == As of November 2019, arketamine is under development for the treatment of depression under the developmental code names PCN-101 by Perception Neuroscience in the United States and HR-071603 by Jiangsu Hengrui Medicine in China. Arketamine failed to show antidepressant effectiveness in a controlled phase 2a clinical trial.
Neuromuscular drugs are chemical agents that are used to alter the transmission of nerve impulses to muscles, causing effects such as temporary paralysis of targeted skeletal muscles. Most neuromuscular drugs are available as quaternary ammonium compounds which are derived from acetylcholine (ACh). This allows neuromuscular drugs to act on multiple sites at neuromuscular junctions, mainly as antagonists or agonists of post-junctional nicotinic receptors. Neuromuscular drugs are classified into four main groups, depolarizing neuromuscular blockers, non-depolarizing neuromuscular blockers, acetylcholinesterase inhibitors, and butyrylcholinesterase inhibitors. Clinically, neuromuscular drugs are used in anesthesia to cause paralysis of targeted skeletal muscles. It is most commonly applied in endotracheal intubation by reducing the incidence of hoarseness in vocal cords and esophageal injuries. It is also applied to improve surgical operating conditions by aiding mechanical ventilation in patients with lowered lung compliance. Other than surgical indications, neuromuscular drugs can also be indicated for the use of Alzheimer's disease, Parkinson's disease, etc. Common adverse effects of neuromuscular drugs include abnormal heart rate, blood pressure, and cardiac output.
=== June === June 1 A firefighter is killed and another injured in a shooting at a Los Angeles County Fire Department station in Santa Clarita. A special election is held in New Mexico to fill a vacancy in its 1st congressional district left by Deb Haaland when she resigned to become President Biden's Secretary of the Interior. Democrat Melanie Stansbury wins with 79,837 of the 132,262 votes cast (60.36%). COVID-19 pandemic SARS-CoV-2 Delta variant becomes the dominant strain of COVID-19 in the United States. COVID-19 vaccines – Moderna seeks full approval from the FDA for the Moderna COVID-19 vaccine. Michigan lifts several face mask requirements at outdoor gatherings and loosens them at indoor gatherings and businesses. Fully vaccinated people are allowed to not wear masks in public, but unvaccinated and partially vaccinated people are still required to do so. June 2 – Paul Allard Hodgkins, a Tampa man who was seen in the U.S. Senate chamber during the January 6 riot at the United States Capitol, pleads guilty, making him the second suspect to do so after Jon Schaffer. June 3 – The FBI announces that it has opened an investigation into Postmaster General Louis DeJoy over campaign fundraising. June 4 Facebook's Oversight Board announces its ban on former President Donald Trump's personal account will last until January 2023. Trump was originally banned for posting a message supporting the January 6 insurrectionists.
== Structure == The LRP1 gene encodes a 600 kDa precursor protein that is processed by furin in the trans-Golgi complex, resulting in a 515 kDa alpha-chain and an 85 kDa beta-chain associated noncovalently. As a member of the LDLR family, LRP1 contains cysteine-rich complement-type repeats, EGF (gene) repeats, β-propeller domains, a transmembrane domain, and a cytoplasmic domain. The extracellular domain of LRP1 is the alpha-chain, which comprises four ligand-binding domains (numbered I-IV) containing two, eight, ten, and eleven cysteine-rich complement-type repeats, respectively. These repeats bind extracellular matrix proteins, growth factors, proteases, protease inhibitor complexes, and other proteins involved in lipoprotein metabolism. Of the four domains, II and IV bind the majority of the protein's ligands. The EGF repeats and β-propeller domains serve to release ligands in low pH conditions, such as inside endosomes, with the β-propeller postulated to displace the ligand at the ligand binding repeats. The transmembrane domain is the β-chain, which contains a 100-residue cytoplasmic tail. This tail contains two NPxY motifs that are responsible for the protein's function in endocytosis and signal transduction.
Simon and Schuster. ISBN 978-1-4262-2005-0. Archived from the original on January 8, 2023. Retrieved January 8, 2023. Gainor, Chris (2001). Arrows to the Moon: Avro's Engineers and the Space Race. Burlington, Ontario: Apogee Books. ISBN 1-896522-83-1. Archived from the original on July 23, 2008. Retrieved August 2, 2019. Gatland, Kenneth (1976). Manned Spacecraft, Second Revision. New York: Macmillan Publishing Co., Inc. ISBN 0-02-542820-9. Hall, Rex; Shayler, David J. (2001). The Rocket Men: Vostok & Voskhod, The First Soviet Manned Spaceflights. New York: Springer–Praxis Books. ISBN 1-85233-391-X. Hall, Rex; Shayler, David J. (2003). Soyuz: A Universal Spacecraft. New York: Springer–Praxis Books. ISBN 1-85233-657-9. Hardesty, Von; Eisman, Gene (2007). Epic Rivalry: The Inside Story of the Soviet and American Space Race. Foreword by Sergei Khrushchev. Washington: National Geographic Society. ISBN 978-1-4262-0119-6. Harford, James J. (1997). Korolev: How One Man Masterminded the Soviet Drive to Beat America to the Moon (1 ed.). New York: John Wiley & Sons. ISBN 0-471-14853-9. Hepplewhite, T.A. (1999). The Space Shuttle Decision: NASA's Search for a Reusable Space Vehicle. Washington, DC: NASA. Jones, Eric M. (January 1, 2010). "Apollo 11 Lunar Surface Journal". Apollo Lunar Surface Journal. Internet. Archived from the original on January 16, 2012. Retrieved August 15, 2010. Kraft, Christopher C. (2001). Flight: My Life in Mission Control. New York: Dutton. ISBN 0-525-94571-7. Murray, Charles; Cox, Catherine Bly (1990). Apollo: The Race to the Moon.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
Animal experiments form the bulk of the published record. Rodent models of tendon, ligament, bone, and gut injury are the most common designs. Controlled human trials are rare, which limits confidence in any clinical claim.